Research Radartracking 1,762 published studies · 471 human · 11 safety signals · 58 clinical trials · 44 cancer pages · updated Sep 2026Open the Research Map →

Pineoblastoma

A plain-English summary of the published research on Pineoblastoma, reviewed and approved by our editors — not a hand-curated clinical overview.

Research summary · reviewed
Educational only: This page is not medical advice. Coordinate decisions with your oncology team.

Reviewed Jun 2026 · OncoForge editorial · How we review →

AI extractedhuman reviewedsources checkedretractions suppressed· last updated Jun 2026

Evidence at a glanceHuman trial / meta-analysisMixed results⚠ Studies disagree
53 published studies that name Pineoblastoma23 human studies approved & graded (trial, observational, or meta-analysis)23 human clinical studies in the Pineoblastoma corpus338 source documents in the Pineoblastoma corpus

last checked June 19, 2026

Why this grade?

Human trial / meta-analysis — Includes human trial or meta-analysis evidence.

  • 23 human · 3 animal · 0 lab · 27 review/other
  • Most authoritative study: A systematic review of adult pineoblastoma
  • Studies disagree on the reported direction (conflict flagged).
  • Findings conflict across studies
  • Effect sizes reported in only 23 of 53 studies

Computed deterministically from the studies’ types and reported outcomes — not written by AI, and not a claim that anything works.

What the guidelines say

NCI PDQESMONCCNASCO

We link the authoritative guidelines rather than reproduce them. Below, the treatments on this page are split into standard care, guideline or regulatory options, supportive care, and studied but not standard so established care is not mixed with experimental or supportive items.

Studied, not standard - investigational
  • surgery
  • endoscopic surgery
  • proton therapy
  • craniospinal irradiation
  • Gamma Knife radiosurgery
  • cisplatin-based chemotherapy
  • high-dose chemotherapy + ABMT
  • methotrexate
  • carboplatin
  • temozolomide

Read the guidelines

Cancer-specific deep links aren’t curated yet — these search the authoritative sources for Pineoblastoma.

Treatment map: Pineoblastoma

Open as a full page →

Standard care plus every compound studied in the literature (each cited) and graded by evidence, organized by clinical readiness. A category, not a verdict that anything works — confirm anything here with your oncology team.

11
Interventions
0
Standard of care
9
Tested in people
2
Lab / animal
0
Named in lit.
3
Classes
Standard of care (0) Guideline option (0) Tested in people (9) Lab / animal only (2) Named in the literature (0)

Tested in people, by trial phase: Phase III ×1 · phase not reported ×8

Clinical evidence
Preclinical evidence
Standard of care
Guideline option
Tested in people
Lab / animal only
Named in the literature
Surgery & procedures
—
—
2
—
—
Radiotherapy
—
—
4
—
—
Chemotherapy
—
—
3
2
—

Columns group into clinical evidence (used in, or tested on, people) and preclinical evidence (lab/animal, or only named in the literature). Cell = number of interventions; a dashed cell means none recorded there.

Investigational & adjunct compounds — detail (11)
Phase III trial (1)
methotrexateoff-label
Meta-analysis (8)
cisplatin-based chemotherapycraniospinal irradiation· Adjuvant (after surgery)endoscopic surgeryGamma Knife radiosurgery· First-line (advanced disease)Gamma Knife radiosurgeryhigh-dose chemotherapy + ABMTproton therapysurgery

"Tested in people" rows show the highest trial phase found in that compound's cited human studies (Phase I–IV; "phase not reported" = a human study with no phase tag). "Studied" = named in the cited literature for this cancer. "FDA ✓" = FDA-approved for this cancer; "off-label" = an FDA-approved drug used outside its approved indications (per openFDA). Not a claim that anything works.

Reported figures

Get cited updates on Pineoblastoma
A monthly email when the research changes — $10/mo. Manage follows
Follow Pineoblastoma

Snapshot

The essentials in ~60 seconds — every line is drawn from the cited sources below.

What it is
Pineoblastoma is a rare, WHO grade IV pineal parenchymal tumour that mainly arises at a younger age and is prone to spreading through the cerebrospinal fluid, so staging must document localized versus disseminated disease. [1][2][3]
Survival
In a pooled series of 108 adult cases the median overall survival was 59 months and the 5-year overall survival was 49.5%. [2]
Standard treatment
Diagnosis is driven by imaging with histologic confirmation by biopsy except for certain germ cell tumours identified by markers; management commonly involves surgical resection (aiming for gross- or subtotal resection) with malignant tumours frequently followed by chemotherapy and radiotherapy, and receipt of radiotherapy was associated with lower hazard of death in a pooled adult series. [1][2]
Key test
Measure AFP and HCG in serum/CSF to identify pineal-region germ cell tumours (which can obviate biopsy); molecular classification into PB-Group 1, PB-Group 2, PB-Group 3, RB and MYC defines distinct clinico-pathologic and survival subgroups. [1][2]
Biggest challenge
The main clinical problems are a high rate of recurrence with a propensity for CSF dissemination and very limited adult-specific evidence to clarify optimal treatment approaches. [2][3]

Ask about Pineoblastoma

Answers come only from the cited sources on this page — with the supporting evidence shown. If the sources here don't cover your question, it will say so. Educational information, not medical advice.

Key numbers & factors

Biomarkers

  • AFP / HCGActionableidentify pineal-region germ cell tumours in serum/CSF and may obviate biopsy [1]
  • Molecular subgroup (PB-Group 1, PB-Group 2, PB-Group 3, RB, MYC) · classify pineoblastoma into prognostic clinico-pathologic groups [2]

9 sections — tap any heading to expand its cited detail. Key points are above.

OverviewPineal region tumours are rare, mainly arise at a younger age, and include pineoblastoma among other histologies. Pineoblastoma is classified as a WHO grade IV tumour with a high rate of recurrence and propensity for spread via the cerebrospinal fluid (CSF).2 points
  • Pineal region tumours are rare, mainly arise at a younger age, and include pineoblastoma among other histologies. [1]
  • Pineoblastoma is classified as a WHO grade IV tumour with a high rate of recurrence and propensity for spread via the cerebrospinal fluid (CSF). [2]
EpidemiologyPineal region tumours are rare. Primary pineal tumours make up a small fraction of intracranial malignancies, pineal tumours are a heterogeneous group in children, and pineoblastoma is a common pineal parenchymal subtype.3 points
  • Primary tumours of the pineal gland are rare and account for 0.1%-0.3% of intracranial malignancies. [2]
  • Pineoblastoma accounts for approximately 45% of all pineal parenchymal tumour subtypes. [2]
  • Tumours of the pineal region represent a rare and heterogeneous group of pediatric intracranial neoplasms, accounting for 3-8% of childhood brain tumors in published series. [3]
Key biomarkersGerm cell tumours in the pineal region — but not pineoblastoma — can sometimes be identified by elevated tumour markers in CSF and serum such as alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG). Recent molecular characterisation has segregated pineoblastoma into five molecular subgroups (PB-Group 1, PB-Group 2, PB-Group 3, RB and MYC) with distinct clinico-pathologic and survival features.2 points
  • Germ cell tumours in the pineal region — but not pineoblastoma — can sometimes be identified by elevated tumour markers such as alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG) in CSF and serum. [1]
  • Recent molecular characterisation has segregated pineoblastoma into five molecular subgroups: PB-Group 1, PB-Group 2, PB-Group 3, RB and MYC, each with distinct clinico-pathologic and survival features. [2]
Standard managementPineal region tumors are typically evaluated with imaging and require histologic diagnosis by biopsy except when specific germ cell tumor markers identify the lesion; they commonly produce obstructive hydrocephalus and mass-effect symptoms such as headache, nausea, vomiting, and impaired gait stability. Management centers on surgical resection — benign pineal region tumors may be managed with radical resection alone, while malignant tumors commonly require additional chemotherapy and radiotherapy after surgical removal.3 points
  • Imaging is the primary diagnostic tool for pineal region tumours, and histologic diagnosis requires biopsy except for certain germ cell tumours identified by markers. [1]
  • These tumours often lead to obstructive hydrocephalus and commonly cause symptoms related to mass effect such as headache, nausea, vomiting, and impaired gait stability. [1]
  • Benign pineal region tumours may be treated with radical resection alone whereas malignant tumours often require additional chemotherapy and radiotherapy after surgical removal. [1]
Treatments & compounds studiedEight entries covering procedure_device, radiotherapy, and chemotherapy approaches to pineoblastoma are reported.8 treatments

Chemotherapy

  • cisplatin-based chemotherapy: Chemotherapy regimens reported in adult pineoblastoma series varied considerably, and where reported a cisplatin-based schedule was used in the majority of patients who received chemotherapy. [2]
  • high-dose chemotherapy + ABMT: Some paediatric series of pineal/medulloblastoma-type tumours included high-dose chemotherapy with autologous bone marrow transplant (ABMT) as part of multimodality treatment prior to proton therapy. [4]

Radiotherapy

  • proton beam therapy · proton therapy: Proton beam therapy has been adopted as the primary radiotherapy modality for selected paediatric CNS tumours in children and young adults (age up to 25 years), providing smaller volumes of non-target irradiated normal tissue compared with photon radiotherapy largely due to the near complete elimination of exit dose. [4]
  • craniospinal irradiation: Adjuvant (after surgery)In a pooled series of adult pineoblastoma cases, the majority (94 of 108) received adjuvant radiotherapy and of those, 51 (54.3%) were treated with craniospinal irradiation (CSI). [2]
  • Gamma Knife radiosurgery · 2 findings
    • First-line (advanced disease)Gamma Knife stereotactic radiosurgery (GKSR) as primary treatment for pineal region tumours achieved local control in 80.3% of cases at a median 36-month follow-up in a pooled analysis. [5]
      local control 80.3%overall mortality 13.2%radionecrosis rate 6%
      Source quotes
      • “At a median 36-month follow-up, local control was achieved in 80.3% of cases.”
      • “Overall mortality was 13.2%.”
      • “The radionecrosis rate was 6%, and cystic degeneration was observed in 2%.”
    • In the pooled Gamma Knife series, overall mortality was 13.2% and the radionecrosis rate was 6%. [5]
      local control 80.3%overall mortality 13.2%radionecrosis rate 6%
      Source quotes
      • “At a median 36-month follow-up, local control was achieved in 80.3% of cases.”
      • “Overall mortality was 13.2%.”
      • “The radionecrosis rate was 6%, and cystic degeneration was observed in 2%.”

Procedures & devices

  • surgical resection · surgery: Microsurgical approaches for pineal region tumours include supracerebellar infratentorial (SCITA), occipital transtentorial (OTA), occipital interhemispheric transtentorial (OITA), and transcallosal routes, and endoscopic or endoscope-assisted techniques are also used. [3]
  • endoscopic surgery: Minimally invasive (endoscopic) techniques increasingly complement traditional microsurgical routes to reduce morbidity and improve CSF management. [3]
Staging & risk1 point
  • Sources describe pineoblastoma as having a high rate of recurrence and a propensity to spread via the cerebrospinal fluid (CSF); staging should therefore document whether disease is localized or disseminated. [2]
PrognosisIn a pooled series of 108 adult pineoblastoma cases the median overall survival was 59 months and the 5-year overall survival was 49.5%. In multivariate analysis, receipt of radiotherapy was associated with a substantially lower hazard of death (HR 0.16; p < 0.001), and patients who underwent surgery (GTR or STR) had superior overall survival at 5 and 10 years.3 points
  • In a pooled series of 108 adult pineoblastoma cases the median overall survival was 59 months and the 5-year overall survival was 49.5%. [2]
  • In multivariate analysis of the pooled adult series, receipt of radiotherapy was associated with a statistically significant lower hazard of death (HR 0.16; p < 0.001). [2]
  • Kaplan–Meier analysis in the pooled adult series showed that patients who underwent surgery (GTR or STR) had superior overall survival at 5 and 10 years (p = 0.009, p = 0.018). [2]
Safety & interactionsProton beam therapy may reduce late adverse events by reducing irradiation of non-target normal tissue compared with photon radiotherapy, but the evidence comes mainly from non-randomised studies and modelling assumptions and no randomised controlled trials comparing proton with photon radiotherapy were identified in the included studies.1 point
  • Proton beam therapy is reported to have the potential to reduce late adverse events by reducing irradiation of non-target normal tissue compared with photon radiotherapy, but the evidence base consists largely of non-randomised studies and modelling assumptions; no randomised controlled trials comparing proton with photon radiotherapy were identified in the included studies. [4]
What we don't know yetImportant evidence gaps remain: adult pineoblastoma care is usually extrapolated from pediatric data because adult-specific studies are limited; prospective multicentric research is needed to define surgical strategies for pediatric pineal region tumours; and further studies are required to validate pooled Gamma Knife radiosurgery findings and to guide selection based on presumptive diagnosis.3 points
  • Multicentric prospective studies are needed to establish evidence-based surgical strategies for pediatric pineal region tumours. [3]
  • Further studies are needed to validate apparent efficacy and safety findings from pooled Gamma Knife radiosurgery reviews and to guide selection based on presumptive diagnosis. [5]
  • Sources describe limited adult-specific evidence—mainly single-institution retrospective analyses and a few case reports—insufficient to clarify treatment options. [2]

Common questions

What is Pineoblastoma?

Pineal region tumours are rare, mainly arise at a younger age, and include pineoblastoma among other histologies. Pineoblastoma is classified as a WHO grade IV tumour with a high rate of recurrence and propensity for spread via the cerebrospinal fluid (CSF).

How common is Pineoblastoma?

Pineal region tumours are rare. Primary pineal tumours make up a small fraction of intracranial malignancies, pineal tumours are a heterogeneous group in children, and pineoblastoma is a common pineal parenchymal subtype.

Which biomarkers are important in Pineoblastoma?

Germ cell tumours in the pineal region — but not pineoblastoma — can sometimes be identified by elevated tumour markers in CSF and serum such as alpha-fetoprotein (AFP) and human chorionic gonadotropin (HCG). Recent molecular characterisation has segregated pineoblastoma into five molecular subgroups (PB-Group 1, PB-Group 2, PB-Group 3, RB and MYC) with distinct clinico-pathologic and survival features.

How is Pineoblastoma treated?

Pineal region tumors are typically evaluated with imaging and require histologic diagnosis by biopsy except when specific germ cell tumor markers identify the lesion; they commonly produce obstructive hydrocephalus and mass-effect symptoms such as headache, nausea, vomiting, and impaired gait stability. Management centers on surgical resection — benign pineal region tumors may be managed with radical resection alone, while malignant tumors commonly require additional chemotherapy and radiotherapy after surgical removal.

What treatments are studied for Pineoblastoma?

Eight entries covering procedure_device, radiotherapy, and chemotherapy approaches to pineoblastoma are reported.

What is the prognosis for Pineoblastoma?

In a pooled series of 108 adult pineoblastoma cases the median overall survival was 59 months and the 5-year overall survival was 49.5%. In multivariate analysis, receipt of radiotherapy was associated with a substantially lower hazard of death (HR 0.16; p < 0.001), and patients who underwent surgery (GTR or STR) had superior overall survival at 5 and 10 years.

Sources

Every statement above is drawn from these reviewed sources. This page reports what they describe. Sources last checked June 19, 2026.

  1. GuidelineConsensus guidelines for the management of pineal region tumours for low- and middle-income countries · 2024
  2. Systematic reviewA systematic review of adult pineoblastoma · 2024
  3. Systematic reviewSurgical management of pediatric pineal region tumors: an overview of current strategies · 2026
  4. Systematic reviewThe effectiveness and safety of proton beam radiation therapy in children and young adults with Central Nervous System (CNS) tumours: a systematic review · 2024
  5. Systematic reviewPrimary Gamma Knife Radiosurgery for pineal region tumors: A systematic review and pooled analysis of available literature with histological stratification · 2023

What supports this page

The kinds of sources behind this page, strongest at the top. Faint rungs show what is not here yet.

Guideline
2
Meta-analysis
2
Systematic review
5
Randomized trial
2
Clinical trial
16
Observational
2
Case report
71
Review
230
Preclinical
0
Other
8

Living document — last change June 19, 2026: Cancer page updated. 2 recent updates logged.

Pooled evidence across studies

PubMed

Numbers pooled deterministically across 34 published studies that passed our figure-accuracy checks — a quick synthesis, not a formal meta-analysis. Updated 9/4/2026.

Medicines & supplements studied for Pineoblastoma

PubMedFDAClinicalTrials.gov

Every drug, supplement, and other agent the published studies cover for Pineoblastoma, ranked by how strong the evidence is — what studies report, not a recommendation. Tap any to see its full profile.

Medicines · 3

MethotrexateHuman trial / meta-analysisMixed results1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: 5-year EFS for Group 3 MB with methotrexate vs without 70% [39.6–87.2], p=0.037, n=25 PMID 40485042 · response rates 16.7–70 across 7 studies

Most authoritative study: Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group

Based on a single study.
ChemotherapyFDA off-labelPhase 31 studyFull profile →
CarboplatinInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Osseous metastasis of pineoblastoma: a case report and review of the literature

No human studies yet · No numeric effect sizes reported · Based on a single study.
ChemotherapyFDA off-label1 studyFull profile →
TemozolomideInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Osseous metastasis of pineoblastoma: a case report and review of the literature

No human studies yet · No numeric effect sizes reported · Based on a single study.
ChemotherapyFDA off-label1 studyFull profile →

What recent studies report in Pineoblastoma

These are reviewed studies whose abstracts concern Pineoblastoma. Each describes only what that study reported. This is not a claim by OncoForge that any compound helps or harms Pineoblastoma. Most are early lab, animal, or small human studies, and findings often conflict.

53 studies23 human3 animal⚠ Conflicting evidenceMechanism (32)Trial (1)Supportive care (1)

Tracking 53 published studies of Pineoblastoma: 23 in humans, 3 in animals, 27 reviews/other.

Reported direction across studies: 22 positive, 12 mixed, 1 negative, 18 inconclusive.

Findings conflict — both supportive and negative/mixed results exist (see below). Human evidence is limited.

These counts summarize what the studies reported; they are not a measure of whether anything works for Pineoblastoma.

Compounds with studies mentioning Pineoblastoma

Methotrexate (1)Carboplatin (1)Temozolomide (1)
Human · observationalMechanismReported positivePreclinical onlyTier 3 · early human

A tumor-associated photoreceptor signature unifies distinct central nervous system malignancies

Cancer cell · Apr 2026 · Single-cell transcriptomics of pineal parenchymal tumors, integrative computational analyses, lineage-specific perturbation to generate preclinical models, and multi-omic characterization of tumors and models

pineoblastomapineal parenchymal tumorsretinoblastomaGroup 3 medulloblastomacentral nervous system malignancies

The authors performed single-cell transcriptome and multi-omic analyses of pineal parenchymal tumors and generated lineage-perturbed preclinical models to trace cellular origins. They mapped pineoblastoma origins to transient, cycling pinealocyte progenitors and identified a tumor-associated photoreceptor signature (TAPS) that is shared by pineoblastoma, retinoblastoma, and Group 3 medulloblastoma. Components of this photoreceptor signature were found to be selective dependencies across these CNS malignancies. The work proposes a developmental basis for molecular similarities and motivates further studies of these developmentally encoded programs.

Key findings
  • Single-cell transcriptomes from pineal parenchymal tumors map pineoblastoma origins to transient, cycling pinealocyte progenitors during development.
  • Lineage-specific perturbation in the early pineal gland produced preclinical models representative of consensus molecular subgroups.
  • Multi-omic characterization of patient tumors and models uncovered a tumor-associated photoreceptor signature (TAPS) common to pineoblastoma, retinoblastoma, and Group 3 medulloblastoma.
  • Transcriptional activity of the TAPS within respective cellular origins provides a developmental explanation for molecular similarities between these entities.
  • Constituents of the photoreceptor signature are reported as selective dependencies across these anatomically distinct CNS malignancies, motivating future evaluation of developmentally encoded programs as potential vulnerabilities.
Limitations: Abstract does not report sample sizes or detailed cohort information.; Findings are primarily molecular and preclinical; no clinical therapeutic testing or patient outcomes are reported.; Selective dependencies are described but not shown to be therapeutically validated in patients within this study.; The abstract summarizes complex multi-omic and model work but provides no quantitative results or statistical measures..

AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewMechanismInconclusiveModerate evidenceTier 4 · clinical

Histopathology and Molecular Pathology of Pineal Region Tumors

Advances and technical standards in neurosurgery · Jan 2026

pineal region tumorsgerm cell tumorspineal parenchymal tumorspineocytomapineal parenchymal tumor of intermediate differentiation (PPTID)pineoblastomagerminomapapillary tumor of the pineal region

This review chapter summarizes the histopathological features and molecular alterations of pineal-region tumors. It describes the main tumor groups (germ cell tumors and pineal parenchymal tumors), lists PPT subtypes (pineocytoma, PPTID, pineoblastoma), and highlights molecular findings such as microRNA biogenesis and RB pathway alterations in pineoblastoma, KBTBD4 insertions in PPTIDs, MAPK pathway mutations in germinomas, and chromosome 10 loss in papillary tumor of the pineal region.

Key findings
  • Pineal region tumors are rare, accounting for about 1% of central nervous system tumors.
  • The two most common pineal-region tumor types are germ cell tumors (GCTs) and pineal parenchymal tumors (PPTs).
  • PPTs include pineocytomas (well-differentiated), PPTIDs (intermediate differentiation), and pineoblastomas (poorly differentiated/high-grade).
  • Pineoblastoma molecular pathogenesis involves alterations in microRNA biogenesis and the retinoblastoma (RB) pathway.
  • PPTIDs are characterized by small in-frame insertions in KBTBD4.
  • Pineal germ cell tumors likely originate from overmigrated primordial germ cells and show the same histopathological spectrum as gonadal counterparts; germinomas frequently present mutations in the MAPK pathway.
  • Papillary tumor of the pineal region is a distinct ependymal-type tumor that shows loss of chromosome 10 in most cases.
Limitations: This is a narrative review/chapter and does not present original experimental or patient-level data.; Pineal-region tumors are rare (≈1%), so underlying studies and evidence are limited by tumor rarity.; The abstract provides no methodological details, sample sizes, or systematic review methods.; The abstract summarizes molecular associations but does not provide prognostic or therapeutic outcome data..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

ReviewReported positiveLimited evidenceTier 4 · clinical

Pineal Tumors and Pineal Region Tumors

Advances and technical standards in neurosurgery · Jan 2026 · narrative review

pineal region tumorspineal parenchymal tumors (PPTs)pineocytomapineal parenchymal tumor of intermediate differentiation (PPTID)pineoblastoma (PB)papillary tumor of the pineal region (PTPR)desmoplastic myxoid tumor, SMARCB1-mutantgerminomanon-germinomatous germ cell tumor (NGGCT)

This narrative review summarizes current radiotherapy principles for pineal region tumors (various pineal parenchymal tumors and germ cell tumors). It reports recommended radiation approaches and doses by subtype (e.g., adjuvant RT 50-54 Gy for some PPTs, CSI with boost for pineoblastoma, WVI 24 Gy + boost for germinomas) and notes survival outcomes reported in the literature (e.g., >90% 5-year OS for germinoma; >70% 5-year OS for older children with pineoblastoma). The authors highlight use of conformal and particle techniques and call for further dose-volume and biomarker-driven refinement.

Reported effects: adjuvant RT dose (pineocytoma) · adjuvant RT dose (PPTID) · +8 more

Studied with: surgery, chemotherapy.

Key findings
  • For pineocytoma (WHO grade I), gross total resection (GTR) provides excellent outcomes; adjuvant radiotherapy (50-54 Gy) or stereotactic radiosurgery (SRS) is reserved for subtotally resected cases.
  • PPTIDs (grades II-III): GTR is the main prognostic factor; adjuvant RT (50-54 Gy) improves overall survival; CSI (23-36 Gy + boost) is indicated for disseminated disease.
  • Pineoblastoma requires multimodal therapy: CSI (36 Gy + boost to 54-55.8 Gy) combined with chemotherapy yields 5-year OS rates >70% in children ≥3 years, but outcomes are poorer in younger or metastatic patients.
  • Papillary tumor of the pineal region (PTPR) often recurs locally; adjuvant focal RT (~50 Gy) is recommended.
  • Desmoplastic myxoid tumor, SMARCB1-mutant: limited data, but focal RT ≥54 Gy has been used.
  • Pure germinomas are highly radiosensitive and achieve >90% 5-year OS; reduced-volume RT (whole-ventricular irradiation, WVI, 24 Gy + boost) has replaced historical CSI for many cases.
  • Non-germinomatous germ cell tumors (NGGCTs) require combined chemotherapy and RT; CSI + boost achieves 70-90% 5-year OS.
  • Proton therapy and other particle techniques are increasingly used to reduce long-term neurocognitive and secondary malignancy risks.
  • Overall management relies on an integrated approach combining surgery, radiotherapy, and chemotherapy, with growing use of molecular classification to guide risk-adapted treatment.
Limitations: This is a narrative review (no original patient-level data or meta-analytic synthesis reported in the abstract).; Pineal region tumors are rare and heterogeneous, limiting the quality and quantity of evidence for some subtypes.; For some entities (e.g., desmoplastic myxoid tumor, SMARCB1-mutant) the abstract notes limited data supporting management recommendations.; Recommendations appear to be based on aggregated/prior literature rather than prospective randomized data (noted indirectly by review format)..

This review summarizes radiotherapy approaches and reported outcomes for pineal region tumors and is directly relevant to clinical radiotherapy planning for these neoplasms.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed

Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 49

Descriptive and molecular analysis of pineal parenchymal tumors with clinical correlation

BMC cancer · Dec 2025 · descriptive observational analysis with univariate and multivariate survival analysis and methylation profiling

pineal parenchymal tumorspineoblastomapapillary tumor of the pineal regionpineal parenchymal tumor of intermediate differentiation (PPTID)pineocytomatrilateral retinoblastomamedulloblastoma

This observational study analyzed 49 patients with pineal parenchymal tumors and performed DNA methylation profiling on 20 cases. In pineoblastoma patients, younger age was significantly associated with worse overall survival and event-free survival, and metastatic status was associated with worse event-free survival. Methylation profiling separated tumors into multiple molecular groups (for example PB-miRNA-1, PB-RB1, and several single-case entities), illustrating marked heterogeneity.

Reported effects: Age impact on overall survival (OS) — univariate p-value, p=0.003, n=39 · Age impact on event-free survival (EFS) — univariate p-value, p=0.021, n=39 · +11 more

Key findings
  • Study cohort comprised 49 patients with pineal parenchymal tumors, including 39 pineoblastomas.
  • Univariate analysis among pineoblastomas showed age significantly impacted overall survival (OS) (p = 0.003) and event-free survival (EFS) (p = 0.021).
  • Metastatic status impacted EFS in univariate analysis (p = 0.032).
  • In multivariate analysis, only age remained significant for OS (p = 0.028).
  • Methylation classification (on 20 cases) identified groups: PB-miRNA-1 (n = 10), PB-RB1 (n = 1), retinoblastoma-MYCN activated (n = 1), PPTID KBTBD4-altered (n = 1), papillary tumor of the pineal region (n = 1), medulloblastoma WNT activated (n = 1), medulloblastoma non-WNT/SHH (n = 1), CNS embryonal tumor with BRD4-LEUTX fusion (n = 1), and unclassified (n = 3).
Limitations: Relatively small overall sample size (n = 49) and small numbers within subgroups, limiting statistical power.; DNA methylation profiling was performed on a subset (20 of 49) of cases, which may limit representativeness of molecular findings.; Observational/descriptive design without randomization or standardized treatment information reported, limiting causal inference and generalizability.; Several molecular subgroups had only single cases, restricting ability to draw robust subgroup-specific conclusions..

Study supports the use of DNA methylation-based molecular classification for accurate diagnosis and prognostic stratification of pineal parenchymal tumors.

AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMechanismMixed resultsLimited evidenceTier 3 · early humann = 83

Recurrent genetic alterations in epigenetically defined pineoblastoma subtypes

Acta neuropathologica communications · Nov 2025 · molecular profiling of tumor cohort (genome-wide copy-number, methylation, targeted sequencing, mRNA expression)

pineoblastoma

Researchers performed genome-wide copy-number, methylation, targeted DNA sequencing, and mRNA expression analyses on pineoblastoma tumors (83 cases). They confirmed four epigenetic PB subtypes and found subtype-specific recurrent genetic events, notably frequent alterations in microRNA-processing genes (DICER1 and DROSHA), recurrent chromosome 7 gains and chromosome 14 losses (the latter associated with DICER1 mutations), frequent OTX2 gains across subtypes, and that PB-MYC/FOXR2 and PB-RB1 in infants had worse outcomes while PB-miRNA subtypes did not differ in survival in this cohort.

Reported effects: cohort_cases_analyzed 83, n=83 · cases_screened_for_mutations 79, n=79 · +15 more

Key findings
  • Cytogenetics of 83 PB were analyzed by high-resolution genome-wide molecular inversion probe analysis and methylation profiling.
  • Seventy-nine cases were screened for mutations by next-generation DNA panel sequencing and for 25 samples mRNA expression was analyzed using NanoString.
  • Clinical data of 63 patients was available.
  • Cohort composition: 48 PB-miRNA1, 19 PB-miRNA2, 8 PB-MYC/FOXR2, and 8 PB-RB1 cases.
  • PB-miRNA subtype tumors showed frequent microRNA-processing gene alterations: DICER1 mutations (n=19/64), homozygous deletions of the DROSHA locus (n=18/67), and DROSHA mutations (n=12/64).
  • Most frequent cytogenetic aberrations in PB-miRNA cases were chromosome 7 gains (n=31/67) and chromosome 14 losses (n=26/67), with 5 of those showing copy-neutral LOH.
  • Chromosome 14 losses were significantly associated with DICER1 mutations (p < 0.001).
  • OTX2 gain was the most frequent alteration overall, occurring in 37/83 PB across all subtypes.
  • Cases with polyploid cytogenetics were identified in the PB-miRNA subtypes (n=16/67).
  • No survival difference was found between PB-miRNA subtypes in this cohort; PB-MYC/FOXR2 and PB-RB1 in infants showed worse outcome.
Limitations: Observational molecular profiling study without interventional or functional validation experiments in this abstract.; Clinical outcome data were available for only 63 of 83 cases.; Some epigenetic subtypes had small sample sizes (e.g., PB-MYC/FOXR2 n=8, PB-RB1 n=8), limiting power for outcome comparisons.; Associations reported are correlative and do not establish causation..

AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Case reportMechanismInconclusiveLimited evidenceTier 3 · early humann = 2

Elevation of hCG in CSF in pinealoblastoma: a pitfall rescued by pathological examination

Acta neuropathologica communications · Nov 2025 · case series (2 cases)

pineoblastomagerminomapineal region tumour

The authors report two cases of pineoblastoma in which cerebrospinal fluid (CSF) β-hCG was unexpectedly elevated, a finding that could have suggested intracranial germinoma. They note that histopathology remains the diagnostic gold standard but that pineal biopsy is technically challenging, and they call for novel non-invasive biomarkers to improve diagnostic accuracy.

Key findings
  • Two cases of pineoblastoma showed unexpectedly elevated CSF β-hCG levels.
  • Elevated CSF β-hCG in these cases could have led to a misdiagnosis of intracranial germinoma.
  • Histopathological confirmation remains the diagnostic gold standard for pineal region tumours, but pineal biopsy is challenging.
  • The cases highlight the need for development of novel non-invasive biomarkers to improve diagnostic accuracy of intracranial tumours.
Limitations: Very small sample (two case reports) so findings are not generalizable.; No quantitative CSF β-hCG values reported in the abstract.; Observational case descriptions without systematic comparison or prevalence data.; Cannot determine how often pineoblastoma causes elevated CSF β-hCG from these reports alone..

AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human trialTrialMixed resultsModerate evidenceTier 4 · clinicaln = 77

Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group

Neuro-oncology · Oct 2025 · phase 3 randomized controlled trial

Methotrexateembryonal brain tumorsmedulloblastomaGroup 3 medulloblastomaSHH medulloblastomaembryonal tumor with multilayered rosettespineoblastoma

This phase 3 randomized trial tested adding high-dose methotrexate to induction chemotherapy in children ≤36 months with high-risk embryonal brain tumors. Overall complete response rates were similar between arms, but in medulloblastoma patients methotrexate was associated with higher CR (63% vs 30%) and improved 5-year event-free survival in Group 3 medulloblastoma (70% vs 33.3%). No benefit was seen for embryonal tumor with multilayered rosettes or pineoblastoma.

Reported effects: eligible patients 77, n=77 · patients evaluated for response 59, n=59 · +8 more

Studied with: induction chemotherapy, high-dose consolidation chemotherapy with hematopoietic stem-cell infusion.

Key findings
  • Of 77 eligible patients, 59 with detectable disease were evaluated for response and 28 (47.5%) achieved CR; 15/30 (50%) treated with methotrexate compared to 13/29 (45%) without methotrexate (P&#x2005;=&#x2005;0.35).
  • For medulloblastoma (MB), CR was 12/19 (63%) with methotrexate compared to 6/20 (30%) without methotrexate (P&#x2005;=&#x2005;0.039).
  • All SHH subtype MB (n&#x2005;=&#x2005;11) were survivors (molecular characterization retrospective).
  • Five-year event-free survival (EFS) for Group 3 MB was 70% (90% CI: 39.6-87.2) with methotrexate versus 33.3% (90% CI: 15.0-52.9) without (P&#x2005;=&#x2005;0.037).
  • In other embryonal tumors, CR was 3/11 (27%) with methotrexate compared to 7/9 (78%) without (P&#x2005;=&#x2005;0.99).
  • No benefit observed for Embryonal Tumor with Multilayered Rosettes (n&#x2005;=&#x2005;14; EFS 20.0% [90% CI: 1.8-52.5] with methotrexate versus 33.3% [90% CI: 10.8-58.1] without, P&#x2005;=&#x2005;0.58) or pineoblastoma (n&#x2005;=&#x2005;9; EFS 16.7% [90% CI: 1.6-46.1] with methotrexate versus 0% without, P&#x2005;=&#x2005;0.52).
Limitations: Relatively small overall sample size (77 eligible) with smaller numbers in histologic/molecular subgroups; Molecular characterization was conducted retrospectively; Some subgroup analyses involve very small n (e.g., Group 3 MB: 10 vs 15; SHH MB n=11); Tests of significance were one-sided (as stated); Confidence intervals reported are 90% rather than the more conventional 95%.

AI summary of the abstract, published automatically under the strong-evidence tier · Jun 2026; an editor has not yet reviewed it. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMechanismMixed resultsLimited evidenceTier 3 · early humann = 42

FOXR2 activation is not exclusive of CNS neuroblastoma

Neuro-oncology · Sep 2025 · retrospective case series (screening institutional datasets and published institutional cases)

central nervous system neuroblastomahigh-grade gliomadiffuse midline glioma (H3 K27M-mutant)radiation-associated tumorembryonal tumorpineoblastoma

Researchers analyzed 42 human CNS tumors with FOXR2 overexpression from institutional datasets and published cases to describe their histologic, molecular, imaging, and clinical features. FOXR2 activation was found across multiple CNS tumor types (including high-grade gliomas, diffuse midline gliomas, embryonal tumors, and pineoblastomas) and arose by mechanisms such as promoter donation, enhancer hijacking, alternative promoter usage, and truncated LINE-1 retrotransposition. Downstream epigenomic and transcriptomic effects were shared across tumor types, but clinical outcomes differed: FOXR2-positive DMGs and pineoblastomas had very poor 2-year survival, while CNS neuroblastomas showed favorable responses to combined chemotherapy and radiation.

Reported effects: n_total_tumors 42, n=42 · HGG_count 21, n=21 · +9 more

Key findings
  • 42 CNS tumors with FOXR2 overexpression were analyzed.
  • Tumor composition: 21 (50.0%) were high-grade gliomas (HGGs) and 18 (42.9%) were embryonal tumors.
  • HGG subgroup included ten H3 K27M-mutant diffuse midline gliomas and eight radiation-associated tumors.
  • Embryonal subgroup included 11 CNS neuroblastomas and six pineoblastomas.
  • FOXR2 expression was similar between CNS neuroblastoma and other tumor types (P = 0.82).
  • Most FOXR2 activation mechanisms involved structural alterations causing promoter donation and enhancer hijacking from active genes essential for brain development; other mechanisms included alternative promoter activation and truncated LINE-1 retrotransposition.
  • All but two aberrant FOXR2 transcripts incorporated non-canonical, non-coding exons.
  • Gene set enrichment analysis showed shared downstream epigenomic and transcriptomic effects of FOXR2 activation across tumor types.
  • Clinical outcomes varied by tumor type: DMGs and pineoblastomas with FOXR2 overexpression had 0% 2-year overall survival, whereas CNS neuroblastomas 'responded well' to combined chemotherapy and radiation.
Limitations: Retrospective case series assembled from institutional datasets and published cases, with potential selection bias.; Small overall sample size (n=42) and small subgroup sizes limit statistical power.; Heterogeneous cohort (multiple tumor histologies and prior radiation–associated tumors) limits generalizability.; Observational molecular analysis without reported prospective validation or functional in vivo confirmation of mechanisms.; Clinical outcome comparisons are descriptive and may be confounded by differing treatments and patient characteristics..

AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Animal studyMechanismReported positivePreclinical onlyTier 2 · animal

Drosha: a new tumor suppressor in pineoblastoma

Genes & development · Jun 2025 · genetically engineered mouse models

pineoblastoma

Researchers used genetically engineered mouse models that represent different molecular subtypes of pineoblastoma to examine the roles of miRNA-processing enzymes Drosha and Dicer1. They found that loss of either Drosha or Dicer1 partially mimicked the tumorigenic effects of Rb1 deletion by promoting cell cycle progression via derepression of Plagl2 and cyclin D2. The study reports a novel mechanism in which disrupted miRNA processing can drive pineoblastoma development and notes that targeting downstream proliferative drivers could be a potential therapeutic strategy.

Key findings
  • Multiple genetically engineered mouse models representing distinct molecular subtypes of pineoblastoma were developed.
  • Loss of either Drosha or Dicer1 partially mimicked the tumorigenic effects of Rb1 deletion.
  • Loss of Drosha or Dicer1 promoted cell cycle progression through derepression of Plagl2 and cyclin D2.
  • Disrupted miRNA processing is reported as a novel mechanism driving pineoblastoma development.
  • Authors highlight a potential therapeutic strategy of targeting downstream proliferative drivers.
Limitations: Study was performed in mouse models only (no human interventional data reported).; Abstract provides no sample size, statistical details, or quantitative results.; Therapeutic strategy is suggested but not tested in this report..

Direct investigation of molecular drivers of pineoblastoma using mouse models; mechanistic relevance to tumorigenesis.

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Animal studyMechanismReported positivePreclinical onlyTier 2 · animal

An imbalance between proliferation and differentiation underlies the development of microRNA-defective pineoblastoma

Genes & development · Jun 2025

pineoblastomapineal tumor

The authors deleted Drosha or Dicer1 in the developing mouse pineal gland to model microRNA-defective pineoblastoma. These mice developed pineal tumors with loss of microRNAs (notably let-7/miR-98-5p), derepression of microRNA target genes, and upregulation of S-phase genes and developmental homeobox transcription factors. Blocking tumor proliferation promoted expression of pinealocyte maturation markers and reduced some embryonic markers, and inhibiting signaling downstream of the oncofetal transcription factor Plagl2 impaired tumor growth. The study suggests that targeting downstream proliferation drivers may limit growth of tumors caused by loss of microRNA processing.

Key findings
  • Ablation of Drosha or Dicer1 in the developing pineal gland of mice produces pineal tumors characterized by loss of microRNAs, particularly the let-7/miR-98-5p family, and derepression of microRNA target genes.
  • Pineal tumors driven by Drosha or Dicer1 loss show upregulation of S-phase genes and homeobox transcription factors and phenocopy tumors driven by Rb1 loss.
  • Blocking proliferation in these tumors facilitates expression of pinealocyte maturation markers and reduces some embryonic markers, although select embryonic markers remain elevated due to continued absence of the repressing microRNAs.
  • Plagl2 is identified as a microRNA target and an oncofetal transcription factor that regulates progrowth genes; inhibiting Plagl2-related signaling impairs tumor growth.
Limitations: Animal (mouse) genetic-ablation model only — findings not demonstrated in human patients.; Study models genetic loss of microRNA processing (Drosha/Dicer1 ablation), which may not fully recapitulate the diversity of human tumor genetics.; No clinical or human data reported to support translational efficacy or safety of targeting the identified pathways..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Human · observationalMechanismReported positiveLimited evidenceTier 3 · early humann = 9

Germline Pathogenic DROSHA Variants Are Linked to Pineoblastoma and Wilms Tumor Predisposition

Clinical cancer research : an official journal of the American Association for Cancer Research · Apr 2025 · germline and tumor sequencing with cohort prevalence analysis in population biobanks

pineoblastomaWilms tumor

The study sequenced germline and tumor DNA and identified nine children from eight families with heterozygous pathogenic germline DROSHA variants who had pineoblastoma (8) or Wilms tumor (1). A somatic second hit in DROSHA was detected in all eight tumors analyzed, and all pineoblastomas were classified as the miRNA processing-altered 1 subtype. The authors estimated population prevalence of germline DROSHA loss-of-function variants at about 1:3,875 to 1:4,843 and found no evidence for increased adult cancer risk. They suggest considering genetic testing and research-based surveillance for individuals with DROSHA GPVs.

Reported effects: case_count_total 9 · pineoblastoma_count 8 · +3 more

Key findings
  • Nine children from eight families were described with heterozygous germline pathogenic DROSHA variants and diagnoses of pineoblastoma (n = 8) or Wilms tumor (n = 1).
  • A somatic second hit in DROSHA was detected in all eight tumors analyzed.
  • All pineoblastoma tumors analyzed were classified as miRNA processing-altered 1 subtype.
  • Estimated population prevalence of germline DROSHA loss-of-function variants is 1:3,875 to 1:4,843 based on UK Biobank and Geisinger DiscovEHR analyses.
  • No evidence was found for increased adult cancer risk in the datasets analyzed.
  • Authors recommend consideration of genetic testing for DROSHA GPVs in patients with pineoblastoma, Wilms tumor, or related conditions and propose research-based surveillance recommendations.
Limitations: Small case series (nine children from eight families) limits generalizability.; Observational genetic study design cannot prove causality.; Abstract does not provide details of the number of adult cases or follow-up, limiting assessment of adult cancer risk.; Population prevalence estimates are reported without detailed methods or confidence intervals in the abstract..

AI summary of the abstract, human-reviewed · Sep 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

ReviewMechanismReported positiveLimited evidenceTier 4 · clinical

Recent Advances in Pineoblastoma Research: Molecular Classification, Modelling and Targetable Vulnerabilities

Cancers · Feb 2025

pineoblastoma

This review summarizes recent advances in pineoblastoma research, describing major molecular subtypes driven by DICER/DROSHA loss, RB1 loss, or cMYC activation and noting differing prognoses between them. It reports that mouse models have been developed for RB1-, DICER1- and DROSHA-driven subtypes (a MYC-driven model is not yet established) and discusses tumor cell of origin, progression, autophagy, and potential targetable vulnerabilities while highlighting that metastatic disease is incurable and standard treatments can impair neurocognitive function.

Key findings
  • Pineoblastoma comprises several major molecular subtypes: (i) loss of microRNA processing factors DICER and DROSHA, (ii) loss of RB1, and (iii) amplification/induction of cMYC.
  • The DICER/DROSHA subtype is characterized by a relatively good prognosis whereas RB1- and MYC-driven subtypes exhibit exceedingly poor prognosis.
  • Mouse models have recently been established for RB1-, DICER1- and DROSHA-driven pineoblastoma subtypes; a MYC-driven mouse model has not yet been established.
  • The review discusses disease biology including cell of origin, tumor progression, the role of autophagy, and describes targetable vulnerabilities that could inform future precision therapies.
  • Standard treatment (surgery, radiation, systemic chemotherapy) improves survival but compromises neurocognitive function; metastatic pineoblastoma is described as incurable.
Limitations: This article is a review and does not present new primary experimental or clinical data.; Many conclusions discussed are based on recent preclinical models and not yet validated in humans.; A MYC-driven pineoblastoma mouse model has not been established, limiting preclinical study of that high-risk subtype.; Pineoblastoma is a rare disease, which limits available clinical data and may hinder generalizability of findings..

AI summary of the abstract, human-reviewed · Jun 2026. Describes what this study reported, not medical advice. View on PubMed · Full text

Browse all studies mentioning Pineoblastoma →

Where the evidence is

What has been studied, and how strong it is, by topic. A dashed cell means no studies were found for that combination — a gap, not evidence of no effect. Open a row to see its studies.

CompoundHuman evidenceMechanismSafetyTrial
Methotrexate1——1
Carboplatin————
Temozolomide————

Study mix

53 published studies by what they were done in. Lab and animal findings often do not carry over to people.

23 Human3 Animal27 Review/other
Reported directionReported positive22Mixed results12Reported negative1Inconclusive18

Compounds with reported-positive results in Pineoblastoma

Where at least one study reported a positive result, shown with the full picture, not just the wins. Positive results are more likely to be published, and most of these are early lab or animal studies that may not translate to people. This reports what studies found, not what works.

Preclinical only: lab / animal (2)
Carboplatin1 positive
Limitations: Single-patient case report without a control group; Findings may not be generalizable to other patients; No detailed dosing or toxicity grading provided in the abstract; Durability of response and long-term outcomes are not reported.
Cited positive studies (1)
Temozolomide1 positive
Limitations: Single-patient case report without a control group; Findings may not be generalizable to other patients; No detailed dosing or toxicity grading provided in the abstract; Durability of response and long-term outcomes are not reported.
Cited positive studies (1)

Evidence at a glance: compounds studied in Pineoblastoma

A deterministic grade of what published studies report for each: strength of evidence, the reported direction, and the largest credible effect, strongest-evidence first. This summarizes findings; it is not a claim that anything works.

MethotrexateHuman trial / meta-analysisMixed results1 human

Includes human trial or meta-analysis evidence.

Largest credible effect: 5-year EFS for Group 3 MB with methotrexate vs without 70% [39.6–87.2], p=0.037, n=25 PMID 40485042 · response rates 16.7–70 across 7 studies

Most authoritative study: Phase 3 randomized trial of high-dose methotrexate for young children with high-risk embryonal brain tumors: A report from the Children's Oncology Group

Based on a single study.
CarboplatinInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Osseous metastasis of pineoblastoma: a case report and review of the literature

No human studies yet · No numeric effect sizes reported · Based on a single study.
TemozolomideInsufficient evidenceReported positive

No primary experimental studies yet.

Most authoritative study: Osseous metastasis of pineoblastoma: a case report and review of the literature

No human studies yet · No numeric effect sizes reported · Based on a single study.

What the research shows for Pineoblastoma

A plain-language summary of the reviewed studies OncoForge tracks for Pineoblastoma. It reports what those studies described, not a claim that any compound or therapy helps or harms Pineoblastoma. Most of this evidence is early, and findings often conflict.

  • Studies report that germline DICER1 pathogenic variants are associated with a spectrum of pediatric tumors and that several reviews and expert-consensus documents include pineoblastoma among the CNS manifestations linked to DICER1, based mainly on genetic and case-series evidence.
  • A small retrospective imaging series of children with germline DICER1 variants reported a range of DICER1‑associated malignant and benign lesions and included pineoblastoma among the observed tumors, but the sample size was limited.
  • An international consensus review summarizes diagnostic and treatment approaches for pineal parenchymal tumors and notes recent genomic findings that informed molecular classification refinements; evidence remains limited by the rarity of these tumors.
  • A phase 3 randomized trial studied adding high‑dose methotrexate to induction chemotherapy in children ≤36 months with high‑risk embryonal brain tumors and reported mixed outcomes (with subgroup differences in medulloblastoma), but it did not provide pineoblastoma‑specific data, so applicability is uncertain.

Compounds studied in Pineoblastoma

Methotrexate1 study
In these studies, high‑dose methotrexate was evaluated in a phase 3 randomized trial of young children with high‑risk embryonal brain tumors where results were mixed overall and showed subgroup differences in medulloblastoma, but the trial did not report pineoblastoma‑specific outcomes, limiting applicability to pineoblastoma.

Supportive & alternative options discussed

  • Hyperthermia (heat): Also discussed as a supportive or adjunctive option in brain tumor care, but the studies summarized here did not evaluate hyperthermia for pineoblastoma.
  • Acupuncture: Also discussed as a supportive option for symptom management in people with brain tumors; these studies did not assess acupuncture in pineoblastoma patients.
  • Exercise / prehabilitation: Also discussed as a supportive approach to preserve function and quality of life in brain tumor survivors; the cited studies did not investigate exercise in pineoblastoma specifically.
  • Mind–body (MBSR / CBT): Also discussed as a supportive option for psychological symptom management in brain tumor care; the provided studies did not address mind–body interventions for pineoblastoma.
  • Ketogenic / metabolic therapy: Also discussed by some as a complementary dietary approach for brain tumors, but the studies in this collection did not evaluate the ketogenic diet in pineoblastoma.

What we don’t know yet

  • Do high‑dose methotrexate or other specific chemotherapy regimens provide benefit (or harm) for patients with pineoblastoma specifically?
  • How do molecular subgroups of pineoblastoma (including DICER1‑associated cases) affect optimal therapy and prognosis?
  • What are the long‑term outcomes, late effects, and quality‑of‑life impacts after current multimodality treatments for pineoblastoma in children?
  • What are appropriate surveillance and management strategies for individuals with germline DICER1 variants regarding pineal tumors, based on prospective data?
  • Are there adequately powered, prospective clinical trials focused on pineoblastoma to guide treatment decisions?
Overall, the evidence relevant to pineoblastoma in these studies is limited and mainly consists of genetic/observational reports, expert consensus, and indirect clinical trial data from other embryonal brain tumors, so firm conclusions about specific treatments for pineoblastoma cannot be drawn from this set of studies.

Clinical trials in Pineoblastoma

12 ongoing · 45 completed · tracked from ClinicalTrials.gov. Recruiting is not the same as proven, and completed is not the same as positive — read the results. Not a recommendation.

Completed
16 stopped (terminated / withdrawn / suspended)

Search all trials on ClinicalTrials.gov →

Getting care & support

Nonprofit / Gov

Practical, vetted help for Pineoblastoma — advocacy, paying for treatment, second opinions, and caregivers.

If you’re struggling emotionally, you don’t have to wait.

Advocacy & community

No dedicated organization for this specific cancer is curated yet — these general organizations can help in the meantime.

Financial help

  • PAN Foundation ↗ — Copay assistance funds by diagnosis (funds open and close as money allows). · status changes often — check the fund’s site
  • HealthWell Foundation ↗ — Copay and premium assistance funds by disease. · status changes often — check the fund’s site
  • CancerCare — financial assistance ↗ — Limited grants plus free financial counseling. · status changes often — check the fund’s site
  • Family Reach ↗ — Help with everyday living costs (rent, transport, food) during treatment. · status changes often — check the fund’s site
  • NeedyMeds ↗ — Searchable directory of drug patient-assistance and discount programs. · status changes often — check the fund’s site
What you’ll typically need to apply
  • Your diagnosis and, if you have it, the specific drug/treatment name (from your care team).
  • Insurance details — your member ID card, or a note that you're uninsured (some funds require active insurance, some don't).
  • Proof of income and household size (recent pay stubs, a tax return, or a benefits letter) — most funds are income-based.
  • Your prescriber's contact information; some programs need the clinic to submit part of the application.
  • Apply early and re-check: funds open and close as money is available, so a closed fund may reopen.

General guidance — each program sets its own eligibility. Confirm requirements on the program’s site.

Help paying for the medicines on this page

Second opinions

Caregiver support

We list only non-profit and government resources — never product sellers — and take no affiliate fees. If a link is broken or a resource doesn't meet that bar, tell us.

Heading to an appointment? Get a printable one-page summary — studied compounds, open trials, interactions, and questions to ask.
Bring this to your appointment →